Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 3
Submit an article Journal homepage
138
Views
6
CrossRef citations to date
0
Altmetric
Review

Economic evaluation of osteoarthritis treatment in Europe

Jennifer A Gillette CERGAS-SDA-IPAS Bocconi University, Bocconi, Milan, Italy
&
Rosanna Tarricone CERGAS-SDA-IPAS Bocconi University, Bocconi, Milan, Italy
Pages 327-341 | Published online: 02 Mar 2005

Bibliography

  • WYNNE HA, CAMPBELL M: Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDS). Pharmacoeconomics (1993) 3(2):107–123.
  • HUNSCHE E, CHANCELLOR JVM, BRUCE N: The burden of arthritis and nonsteroidal anti-inflammatory treatment. Pharmacoeconomics (2001) 19\(Suppl. 1):1–15.
  • LORD J, VICTOR C, LITTLEJOHNS P, ROSS FM, AXFORD JS: Economic evaluation of a primary care-based programme for patients with osteoarthritis of the knee. Health 7echnol. Assess. (1999) 3(23):1–51.
  • DOUGLAS M: The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint. Clin. Exp. Rheumatol (2001) 19\(Suppl. 25):59–514.
  • STEELE K, GILLILAND D: Non-steroidal anti-inflammatory drugs - prescribe with caution. J. R. Coll. Gen. Prac. (1988) 38:49–52.
  • MACDONALD TM: Epidemiology and pharnacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (2000) 39\(Suppl. 2):13–20.
  • FREEMANTLE N: Cost-effectiveness of non-steroidal anti-inlammatory drugs (NSAIDs) - what makes a NSAID good value for money? Rheumatology (2000) 39(3):232–234.
  • HUNGIN APS: Nonsteroidal anti-inlammatory drugs: overused or underused in osteoarthritis? Am. J. Med. (2001) 110(148S–11S.
  • EVERS SMAA, VAN WIJK AS,AMENT AJHA: Economic evaluation of mental health care interventions. A review. Health Econ. (1997) 6:161–177.
  • TARRICONE R, MARTELLI E, PARAZZINI F, DARBA J, LE PEN C, ROVIRA J: Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain. Clin. Drug Invent. (2001) 21 (4 453–464.
  • LIAROPOULOS L, SPINTHOURI M, IGHATIADES T, IFANDI G, KATOSTARAS F,DIAMANTOPOULOS E: Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece. Pharmacoeconomics (1998) 14(5):575–588.
  • MOORE RA, PHILLIPS CJ, PELLISSIER JM, KONG SX:Health economic comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. I Med. Econ. (2001) 4:1–17.
  • HAGLUND U, SVARVAR P: The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (2000) 39\(Suppl. 2):51–56.
  • SVARVAR P, ALY A: Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology (2000) 39\(Suppl. 2):43–50.
  • CHANCELLOR JVM, HUNSCHE E, DE CRUZ E SARASIN FP: Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics (2001) 19\(Suppl. 1):59–75.
  • MCCABE CJ, AKEHURST RL,KIRSCH J et al.: Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK. Pharmacoeconomics (1998) 14 (2) :191–199.
  • •The first group to include a COX-2-specific inhibitor, in a study performed on a European population. The study concluded that despite its better safety profile, neburnetome is not always a cost-saving therapy.
  • JANSEN RB, CAPRI S, NUIJTEN MJC, BURRELL A, MARINI MG,HARDENS M: Economic evaluation of meloxicam (7.5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. Br. J. Med. Econ. (1997) 11:9–22.
  • PERIS F, MARTINEZ E, BADIA X, BROSA M: Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs. Pharmacoeconomics (2001) 19(7):779–790.
  • FAGNANI F, BOUVENOT G, VALATJ-P et al.: Medico-economic analysis of diacerein with and without standard therapy in the treatment of osteoarthritis. Pharmacoeconomics (1998) 13(1 Pt 2):135–146.
  • STURKENBOOM MC, ROMANO F, SIMON G et al.: The iatrogenic costs of NSAID therapy: a population study. Arthritis Rheum. (2002) 47 (2) :132–140.
  • •The authors employed an Italian regional database (Friuli-Venezia Giulia), and from the perspective of the Italian NHS, they did not fmd a difference in the iatrogenic costs between COX-non-specific and COX-2-specific inhibitors.
  • CHEVAT C, PENA BM, AL MJ, RUTTON FFH: Healthcare resource utilization and costs of treating NSAID-associated gastrointestional toxicity. A multinational perspective. Pharmacoeconomics (2001) 19\(Suppl. 1):17–32.
  • •In this information-rich cost-analysis study, the authors calculated, when possible, from both the social and payer perspectives, the the cost of treating OA in different countries.
  • BURKE TA, ZABINSKI RA, PETTITT D et al.: A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoecnomics (2001) 19\(Suppl. 1):33–47.
  • PETTITT D, GOLDSTEIN JL, MCGUIRE A, SCHWARTZ S, BURKE T, MANIADAKIS N: Overview of the Arthritis Cost Consequence Evaluation System (ACCESS): a pharmacoeconomic model for celecoxib. Rheumatology (2000) 39\(Suppl. 2):33–42.
  • HAWKEY CJ, KAHAN A, STEINBRUECK K et al.: Gastrointestinal tolerability of melmdcam compared to diclofenac in osteoarthritis patients. Br. Rheumatol (1998) 37:937–945.
  • LEQUESNE M, MERY C, SAMSON M et al.: Indexes of severity for osteoarthritis of the hip and knee. Scand. j Rheumatol (1987) 65(Suppl.):85–89.
  • MEENAN RE MASON JH,ANDERSON JJ et al.: The content and properties of a revised and expanded arthritis impact measurement scales health status questionnaire. Arthritic Rheum. (1992) 35:1–10.
  • BUCQUET D, CONDON S,RITCHIE K: The French version of the Nottingham Health Profile. A comparison of the items weights with those of the sourceversion. Soc. Sci. Med. (1990) 30(7)829–835.
  • HUNT SM, MCKENNA SP, MCEWEN J et al.: Quantitative approach to perceived health status: a validity study. J. Epidemic]. Community Health (1980) 34:281–286.
  • FRIES JF, WILLIAMS CA, BLOCH DA, MICHEL BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am. J. Med. (1991) 91(3):213–222.
  • FAUTREL B, GUILLEMIAN F: Cost of illness studies in rheumatic diseases. Cup: Opin. Rheumatcl. (2002) 14(2):121–126.Websites

Websites

  • www.xe.com/euro.htmlXE.com — Information on the New Euro Currency. Accessed 18th February 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.